Relapsed or refractory (R/R) B-cell malignancies

Clinical trials for Relapsed or refractory (R/R) B-cell malignancies explained in plain language.

Never miss a new study

Get alerted when new Relapsed or refractory (R/R) B-cell malignancies trials appear

Sign up with your email to follow new studies for Relapsed or refractory (R/R) B-cell malignancies, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

New CAR t therapy targets two proteins to fight blood cancers

Disease control Not yet recruiting

This early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safe…

Matched conditions: RELAPSED OR REFRACTORY (R/R) B-CELL MALIGNANCIES

Phase 1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control

Last updated Jun 27, 2026 08:06 UTC

Relapsed or refractory (R/R) B-cell malignancies

Get alerted when new Relapsed or refractory (R/R) B-cell malignancies trials appear

New CAR t therapy targets two proteins to fight blood cancers